381 related articles for article (PubMed ID: 18416598)
21. High-dose compared with intermediate-dose methotrexate in children with a first relapse of acute lymphoblastic leukemia.
von Stackelberg A; Hartmann R; Bührer C; Fengler R; Janka-Schaub G; Reiter A; Mann G; Schmiegelow K; Ratei R; Klingebiel T; Ritter J; Henze G;
Blood; 2008 Mar; 111(5):2573-80. PubMed ID: 18089849
[TBL] [Abstract][Full Text] [Related]
22. A pilot study of intermediate-dose methotrexate and cytosine arabinoside, "spread-out" or "up-front," in continuation therapy for childhood non-T, non-B acute lymphoblastic leukemia. A Pediatric Oncology Group study.
Krance RA; Newman EM; Ravindranath Y; Harris MB; Brecher M; Wimmer R; Shuster JJ; Land VJ; Pullen J; Crist W
Cancer; 1991 Feb; 67(3):550-6. PubMed ID: 1985748
[TBL] [Abstract][Full Text] [Related]
23. Risk factors for delayed elimination of high-dose methotrexate in childhood acute lymphoblastic leukemia and lymphoma.
Nakano T; Kobayashi R; Matsushima S; Hori D; Yanagi M; Suzuki D; Kobayashi K
Int J Hematol; 2021 May; 113(5):744-750. PubMed ID: 33389654
[TBL] [Abstract][Full Text] [Related]
24. Relationship between oral mucositis and high-dose methotrexate therapy in pediatric acute lymphoblastic leukemia.
Maiguma T; Hayashi Y; Ueshima S; Kaji H; Egawa T; Chayama K; Morishima T; Kitamura Y; Sendo T; Gomita Y; Teshima D
Int J Clin Pharmacol Ther; 2008 Nov; 46(11):584-90. PubMed ID: 19000557
[TBL] [Abstract][Full Text] [Related]
25. Population pharmacokinetics of methotrexate in Mexican pediatric patients with acute lymphoblastic leukemia.
Medellin-Garibay SE; Hernández-Villa N; Correa-González LC; Morales-Barragán MN; Valero-Rivera KP; Reséndiz-Galván JE; Ortiz-Zamudio JJ; Milán-Segovia RDC; Romano-Moreno S
Cancer Chemother Pharmacol; 2020 Jan; 85(1):21-31. PubMed ID: 31673826
[TBL] [Abstract][Full Text] [Related]
26. Comparison of long-term neurocognitive outcomes in young children with acute lymphoblastic leukemia treated with cranial radiation or high-dose or very high-dose intravenous methotrexate.
Spiegler BJ; Kennedy K; Maze R; Greenberg ML; Weitzman S; Hitzler JK; Nathan PC
J Clin Oncol; 2006 Aug; 24(24):3858-64. PubMed ID: 16921038
[TBL] [Abstract][Full Text] [Related]
27. The Expression and Activation of the NF-κB Pathway Correlate with Methotrexate Resistance and Cell Proliferation in Acute Lymphoblastic Leukemia.
Canevarolo RR; Cury NM; Yunes JA
Genes (Basel); 2023 Sep; 14(10):. PubMed ID: 37895229
[TBL] [Abstract][Full Text] [Related]
28. Improvement in CNS protective treatment in non-high-risk childhood acute lymphoblastic leukemia: report from the Japanese Children's Cancer and Leukemia Study Group.
Tsurusawa M; Katano N; Yamamoto Y; Hirota T; Koizumi S; Watanabe A; Takeda T; Hatae Y; Yatabe M; Mimaya J; Gushiken T; Nishi K; Anami K; Kikuta A; Kanegane H; Asami K; Nishikawa K; Sekine I; Kawano Y; Iwai A; Furuyama T; Ijichi O; Miyake M; Mugishima H; Fujimoto T
Med Pediatr Oncol; 1999 Apr; 32(4):259-6. PubMed ID: 10102019
[TBL] [Abstract][Full Text] [Related]
29. The evaluation of red blood cell folate and methotrexate levels during protocol M in childhood acute lymphoblastic leukemia.
Oosterom N; Fiocco M; Kloos RQH; van der Sluis IM; Pieters R; van Zelst BD; Smith DEC; van den Heuvel-Eibrink MM; de Jonge R; Heil SG
BMC Cancer; 2020 Sep; 20(1):940. PubMed ID: 32998716
[TBL] [Abstract][Full Text] [Related]
30. Genetic and metabolic determinants of methotrexate-induced mucositis in pediatric acute lymphoblastic leukemia.
den Hoed MA; Lopez-Lopez E; te Winkel ML; Tissing W; de Rooij JD; Gutierrez-Camino A; Garcia-Orad A; den Boer E; Pieters R; Pluijm SM; de Jonge R; van den Heuvel-Eibrink MM
Pharmacogenomics J; 2015 Jun; 15(3):248-54. PubMed ID: 25348617
[TBL] [Abstract][Full Text] [Related]
31. Methotrexate resistance in relation to treatment outcome in childhood acute lymphoblastic leukemia.
Wojtuszkiewicz A; Peters GJ; van Woerden NL; Dubbelman B; Escherich G; Schmiegelow K; Sonneveld E; Pieters R; van de Ven PM; Jansen G; Assaraf YG; Kaspers GJ; Cloos J
J Hematol Oncol; 2015 May; 8():61. PubMed ID: 26022503
[TBL] [Abstract][Full Text] [Related]
32. Germline genetic variations in methotrexate candidate genes are associated with pharmacokinetics, toxicity, and outcome in childhood acute lymphoblastic leukemia.
Radtke S; Zolk O; Renner B; Paulides M; Zimmermann M; Möricke A; Stanulla M; Schrappe M; Langer T
Blood; 2013 Jun; 121(26):5145-53. PubMed ID: 23652803
[TBL] [Abstract][Full Text] [Related]
33. Associations of novel genetic variations in the folate-related and ARID5B genes with the pharmacokinetics and toxicity of high-dose methotrexate in paediatric acute lymphoblastic leukaemia.
Csordas K; Lautner-Csorba O; Semsei AF; Harnos A; Hegyi M; Erdelyi DJ; Eipel OT; Szalai C; Kovacs GT
Br J Haematol; 2014 Aug; 166(3):410-20. PubMed ID: 24712521
[TBL] [Abstract][Full Text] [Related]
34. Monitoring Of High-Dose Methotrexate (Mtx)-Related Toxicity and Mtx Levels in Children with Acute Lymphoblastic Leukemia: A Pilot-Study in Indonesia.
Sari NM; Rakhmilla LE; Bashari MH; Zazuli Z; Suryawan N; Susanah S; Reniarti L; Raspati H; Supriyadi E; Kaspers GJL; Idjradinata P
Asian Pac J Cancer Prev; 2021 Jul; 22(7):2025-2031. PubMed ID: 34319023
[TBL] [Abstract][Full Text] [Related]
35. [Investigation on individualized adjustment of target range of high-dose methotrexate].
Hua Y; Zhao WH; Lu XT; Yang LH; Lu W
Zhonghua Er Ke Za Zhi; 2008 Mar; 46(3):203-8. PubMed ID: 19099710
[TBL] [Abstract][Full Text] [Related]
36. Reduced folate carrier mutations are not the mechanism underlying methotrexate resistance in childhood acute lymphoblastic leukemia.
Kaufman Y; Drori S; Cole PD; Kamen BA; Sirota J; Ifergan I; Arush MW; Elhasid R; Sahar D; Kaspers GJ; Jansen G; Matherly LH; Rechavi G; Toren A; Assaraf YG
Cancer; 2004 Feb; 100(4):773-82. PubMed ID: 14770434
[TBL] [Abstract][Full Text] [Related]
37. Impact of morning versus evening schedule for oral methotrexate and 6-mercaptopurine on relapse risk for children with acute lymphoblastic leukemia. Nordic Society for Pediatric Hematology and Oncology (NOPHO).
Schmiegelow K; Glomstein A; Kristinsson J; Salmi T; Schrøder H; Björk O
J Pediatr Hematol Oncol; 1997; 19(2):102-9. PubMed ID: 9149738
[TBL] [Abstract][Full Text] [Related]
38. High-dose methotrexate in Egyptian pediatric acute lymphoblastic leukemia: the impact of ABCG2 C421A genetic polymorphism on plasma levels, what is next?
El Mesallamy HO; Rashed WM; Hamdy NM; Hamdy N
J Cancer Res Clin Oncol; 2014 Aug; 140(8):1359-65. PubMed ID: 24718721
[TBL] [Abstract][Full Text] [Related]
39. Thiopurine Enhanced ALL Maintenance (TEAM): study protocol for a randomized study to evaluate the improvement in disease-free survival by adding very low dose 6-thioguanine to 6-mercaptopurine/methotrexate-based maintenance therapy in pediatric and adult patients (0-45 years) with newly diagnosed B-cell precursor or T-cell acute lymphoblastic leukemia treated according to the intermediate risk-high group of the ALLTogether1 protocol.
Toksvang LN; Als-Nielsen B; Bacon C; Bertasiute R; Duarte X; Escherich G; Helgadottir EA; Johannsdottir IR; Jónsson ÓG; Kozlowski P; Langenskjöld C; Lepik K; Niinimäki R; Overgaard UM; Punab M; Räty R; Segers H; van der Sluis I; Smith OP; Strullu M; Vaitkevičienė G; Wik HS; Heyman M; Schmiegelow K
BMC Cancer; 2022 May; 22(1):483. PubMed ID: 35501736
[TBL] [Abstract][Full Text] [Related]
40. Accumulation of methotrexate and methotrexate polyglutamates in lymphoblasts and treatment outcome in children with B-progenitor-cell acute lymphoblastic leukemia: a Pediatric Oncology Group study.
Whitehead VM; Shuster JJ; Vuchich MJ; Mahoney DH; Lauer SJ; Payment C; Koch PA; Cooley LD; Look AT; Pullen DJ; Camitta B
Leukemia; 2005 Apr; 19(4):533-6. PubMed ID: 15716987
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
